ArticleEuropean radiology2006
Development of water-soluble metallofullerenes as X-ray contrast media.
Article in European radiology, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Water-soluble endohedral metallofullerenes: new horizons for biomedical applications.Chemical communications (Cambridge, England) · 2023Review
- Hypoxia inducible factor down-regulation, cancer and cancer stem cells (CSCs): ongoing success stories.MedChemComm · 2017Review
- Gd-metallofullerenol nanomaterial as non-toxic breast cancer stem cell-specific inhibitor.Nature communications · 2015Article
- A platform for specific delivery of lanthanide-scandium mixed-metal cluster fullerenes into target cells.ChemistryOpen · 2012Article
- Biomedical activities of endohedral metallofullerene optimized for nanopharmaceutics.Journal of nanoscience and nanotechnology · 2010Article
- AuNP-DG: deoxyglucose-labeled gold nanoparticles as X-ray computed tomography contrast agents for cancer imaging.Molecular imaging and biology · 2010Article
- Suppression of synaptic plasticity by fullerenol in rat hippocampus in vitro.International journal of nanomedicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fullerenes are a new carbonic allotrope having a cage structure. We investigated whether fullerenes containing one or two atoms of heavy metals could be an X-ray contrast material with little adverse effects. One or two atoms of dysprosium (Dy), erbium (Er), gadolinium (Gd), europium (Eu) and lutetium (Lu) were encapsulated into fullerene (C(82)), which was synthesized as a polyhydroxyl form (e.g., Gd@C(82)(OH)n, n=40, Gd - fullerenols). They were dissolved in water at maximum soluble concentrations and subjected to CT number analysis. The CT numbers of the solutions were measured using a 4- or 16-row multidetector CT scanner. The CT number of the water-soluble metallofullerenes were 56.0 HU for Dy@C(82)(OH)(40), 111.5 HU for Er@C(82)(OH)(40), 58.4 HU for Gd@C(82)(OH)(40), 100.9 HU for Eu@C(82)(OH)(40) and 23.3 HU for Lu(2)@C(82)(OH)(40). The CT numbers of the metallofullerenes investigated in the present study were not high enough to be used in the clinic in place of iodinated contrast materials. However, if nanotechnology progresses in the near future, it may prove to have a possibility as an X-ray contrast material.
Indexed as
Identifiers
16344962What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.